Sitemap
- Home
- Dermatology
- Atopic Dermatitis
- Articles
- Resources
- DE:RM – Dermatology Excellence: Redefining Management
- Expert Insights on Advancing the Conversation on Disease Modification in Atopic Dermatitis
- Hot Topics in Atopic Dermatitis
- Dupixent (dupilumab) Resources
- Inside Atopic Dermatitis: The Dupixent (Dupilumab) Podcast Series
- DUPIXENT® (dupilumab) Atopic Dermatitis Patient Support Resources
- Tools
- Atopic Dermatitis
- Respiratory
- Cardiology
- Dyslipidaemia
- Articles
- Praluent® (alirocumab) mechanism of action
- Cardiovascular outcomes for diabetes patients Praluent® (alirocumab)
- ODYSSEY OUTCOMES Efficacy Praluent® (alirocumab)
- FH I & FH II Studies Praluent® (alirocumab)
- ODYSSEY OUTCOMES Safety Profile Praluent® (alirocumab)
- Therapeutic indications for Praluent® (alirocumab)
- NICE and SMC Guidance Praluent® (alirocumab)
- Dosing options – customise your patient’s treatment with Praluent® (alirocumab)
- ODYSSEY OUTCOMES Trial Design Praluent® (alirocumab)
- Praluent® (alirocumab) Administration
- Specific characteristics of Praluent® (alirocumab)
- Unmet Needs in Dyslipidaemia
- Resources
- Education
- Articles
- Dyslipidaemia
- Rare Disease
- Other Topics
- Vaccines
- Diabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Articles
- Hospitalisation rates with basal insulin in adults with T2D
- Help Managing Insulin-Related Weight Gain in Type 2 Diabetes: Practical Guidance
- Patient satisfaction with Toujeo (insulin glargine 300 Units/mL) in adults with T2D
- Head to Head Studies
- The Importance of Glycaemic Control: Strategies to Support People with Type 2 Diabetes
- Events
- Education
- Articles
- Transplant
- Transplant
- Articles
- Education
- Patient Case Study Presentations - EBMT 2025
- EBMT 2024: The late effects of chronic GvHD: The challenge of long-term management
- EBMT 2024: QoL and chronic GvHD
- EBMT 2024: Treatment of steroid refractory chronic GvHD
- InTen Nurse Forum - ACCEND Framework
- EBMT 2024: Frontline treatment of chronic GvHD
- InTen Nurse Forum: What is chronic GvHD?
- Patient Case Study 8: Treatment of Severe cGVHD
- Patient Case Study 9: Treatment of cGVHD with Steroid-related Complications
- EBMT 2024: Roundtable: Exploring clinical cases
- EBMT 2024: Expanding the cGvHD treatment paradigm with novel therapeutics
- EBMT 2024: Advances in the biology of chronic GvHD
- EBMT 2024: Pulmonary chronic GvHD: The need for early identification and improved management
- Transplant
- Oncology
- Neurology
- Products
- Avaxim®
- Cerdelga®▼(Eliglustat)
- Efluelda TIV-HD▼
- Supemtek TIVr▼
- Vaxigrip Trivalent Influenza Vaccine
- Cablivi®
- Avaxim® Junior hepatitis A vaccine (inactivated, adsorbed)
- Praluent®
- Beyfortus®▼ (nirsevimab)
- Myozyme®
- Repevax®
- Revaxis®
- Cerezyme®
- REZUROCK®▼
- Lantus®
- Verorab®
- Toujeo®
- Trurapi®▼
- Typhim Vi (Typhoid Polysaccharide Vaccine)®
- SARCLISA® (isatuximab) RRMM
- Fabrazyme®
- MenQuadfi
- Dupixent® (dupilumab) Atopic Dermatitis
- Stamaril® (Yellow Fever Vaccine Live)
- DUPIXENT® (dupilumab) Severe Asthma
- SARCLISA® (isatuximab) Ti NDMM
- Clexane®
- Nexviadyme® ▼
- Aldurazyme®
- Dupixent® (dupilumab) Prurigo Nodularis
- Therapeutic Areas
- Sitemap
- Sign Up
- Sign In
- Terms of Use
- Privacy Policy
- Cookie Policy